Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Audio By Carbonatix

DALLAS--(BUSINESS WIRE)--Feb 9, 2026--

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings.

Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11 th hosted at the Lotte New York Palace in New York, NY.

Additionally, on March 4 th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46 th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA.

March 10-12, Dr. Wagner will be attending the Barclays 28 th Annual Global Healthcare Conference hosted at the Loews Miami Beach Hotel in Miami Beach, FL.

About Forte

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.

Source: Forte Biosciences, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260209147037/en/

CONTACT: LifeSci Advisors

Mike Moyer, Managing Director

[email protected]

KEYWORD: MASSACHUSETTS NEW YORK FLORIDA TEXAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH OTHER SCIENCE GENERAL HEALTH RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Forte Biosciences, Inc.

Copyright Business Wire 2026.

PUB: 02/09/2026 04:01 PM/DISC: 02/09/2026 04:03 PM

http://www.businesswire.com/news/home/20260209147037/en